EYSINS, Switzerland, April 3, 2025 /PRNewswire/ --Today, AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex ® ...
As sequencing projects of microbial organisms are being completed, a large number of genes of potential biological and medical relevance are classified as 'unknown' because their unique sequence and ...
EYSINS, Switzerland, Feb. 10, 2025 /PRNewswire/ -- AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex ® Celiac ...
AliveDx, an established commercial-stage in-vitro diagnostics company, announces it has submitted 510(k) premarket notification to the US Food and Drug Administration (FDA) for the MosaiQ AiPlex ...
MiRNA microarray kits and reagents market is experiencing robust growth driven by rising demand for precision diagnostics, biomarker discovery, and translational research. Expansion of oncology ...
All reagents and multiplex microarray magazines are equipped with RFID tags to save time while avoiding manual errors. Unique combination of tests The MosaiQ AiPlex CTDplus assay enables a syndromic ...
The MosaiQ AiPlex CD is designed to improve the accuracy and speed of celiac disease diagnosis while simplifying laboratory workflows The MosaiQ AiPlex CD multiplex assay, which received IVDR-CE mark ...
The MosaiQ AiPlex CD is designed to improve the accuracy and speed of celiac disease diagnosis while simplifying laboratory workflows EYSINS, Switzerland, Feb. 10, 2025 /PRNewswire/ -- AliveDx ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results